← Leaderboards
David Matthew Kurtz
Stanford University
$956,520
Attributed
$956,520
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $191.3K · FY2019–23$200K$150K$100K$50K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$956,520 · 1
By mechanism
K08$956,520 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Michael L Whitfield$14,056,386
- Maximilian Diehn$12,346,945
- Jerome A Yesavage$8,719,810
- Sylvia Katina Plevritis$44,733,712
- Yvonne A. Maldonado$6,555,051
Others in their field
Other Emerging Leaders on “S Lymphoma”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$22,138,591
- Leonard Freedman · Leidos Biomedical Research, Inc.$10,332,151
- Kathleen Nicol · Research Inst Nationwide Children'S Hosp$7,187,946
- Javeed Iqbal · University Of Nebraska Medical Center$5,566,166
- John Karijolich · Vanderbilt University Medical Center$5,446,739
Research focus
S LymphomaComputational BiologyCar T Cell TherapyBiological HeterogeneityAreaBiologyAdultBlood SpecimenB Lymphoid MalignancyCancer DetectionCancer PatientBiological MarkersCancer TherapyCareerDetectionCd19 GeneCellsChimeric Antigen ReceptorChimeric Antigen Receptor T CellsClinical HeterogeneityClinically SignificantClinical OncologyCohortDiagnosis
Grant awards (5)
Molecular Characterization and Personalized Approaches to Non-Hodgkin Lymphoma from Circulating Tumor DNA$191,304
K08 · FY2023 · CA · contact PI
Molecular Characterization and Personalized Approaches to Non-Hodgkin Lymphoma from Circulating Tumor DNA$191,304
K08 · FY2022 · CA · contact PI
Molecular Characterization and Personalized Approaches to Non-Hodgkin Lymphoma from Circulating Tumor DNA$191,304
K08 · FY2021 · CA · contact PI
Molecular Characterization and Personalized Approaches to Non-Hodgkin Lymphoma from Circulating Tumor DNA$191,304
K08 · FY2020 · CA · contact PI
Molecular Characterization and Personalized Approaches to Non-Hodgkin Lymphoma from Circulating Tumor DNA$191,304
K08 · FY2019 · CA · contact PI